FDA Accepts & Gives Priority Review to Intellia’s BLA for HAE Drug
Intellia Therapeutics NTLA announced that the FDA has accepted the biologics license application (BLA) seeking approval for lonvoguran ziclumeran…
After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…